{"filing":{"accession_number":"0001213900-26-080622","cik":"0001873875","ticker":"IXHL","company_name":"Incannex Healthcare Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"ea0298674-8k_incannex.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/ea0298674-8k_incannex.htm"},"events":[{"id":19826,"run_id":17840,"accession_number":"0001213900-26-080622","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses commencement of participant screening in the DReAMzz Phase 2 dose confirmation study for IHL-42X in obstructive sleep apnea, representing a material clinical development milestone. The company notes this is \"another major milestone in the advancement of IHL-42X towards Phase III development\" and highlights FDA Fast Track designation, positive prior Phase 2 data (83% AHI reduction), and operational progress including CRO appointment and manufacturing completion. This is a significant operational/clinical advancement for a clinical-stage biopharmaceutical company, but does not fit the specific named categories (not earnings, M\u0026A, impairment, litigation, etc.), making operational_other the most appropriate classification.","company_name":"Incannex Healthcare Inc.","ticker":"IXHL","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":19026,"accession_number":"0001213900-26-080622","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses commencement of participant screening in the DReAMzz Phase 2 dose confirmation study for IHL-42X in obstructive sleep apnea, representing a material clinical development milestone. The company notes this is \"another major milestone in the advancement of IHL-42X towards Phase III development\" and highlights FDA Fast Track designation, positive prior Phase 2 data (83% AHI reduction), and operational progress including CRO appointment and manufacturing completion. This is a significant operational/clinical advancement for a clinical-stage biopharmaceutical company, but does not fit the specific named categories (not earnings, M\u0026A, impairment, litigation, etc.), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T11:31:37.710802+00:00","company_name":"Incannex Healthcare Inc.","ticker":"IXHL","filing_date":"2026-07-23"}]}